The International Stroke Conference (ISC) attracts thousands of neurologists each year to network with fellow experts and watch compelling presentations on the very latest advances in clinical care, science, and education. Joining those presentations for the first time was a rather provocative topic – gender disparities among the very presenters themselves.
A team of surgeons is working to identify the most effective strategy to treat acute pain after injury while minimizing the amount of opioids prescribed to trauma patients, building on a previous project that decreased use of the highly addictive class of drugs by 40 percent.
Pregnant women face a much greater risk of having a fatal, but less common, type of stroke caused by bleeding into the brain, according to results of two studies presented by The University of Texas Health Science Center at Houston (UTHealth) at the International Stroke Conference 2019.
The Houston Emergency Response Opioid Engagement System (HEROES) was recently awarded two grants that will help fund the opioid intervention program through the end of 2020. James Langabeer, PhD, MBA, a professor at The University of Texas Health Science Center at Houston (UTHealth), created the program to provide comprehensive treatment for opioid abusers, gain a more thorough understanding of the epidemic in Houston, and work toward getting the highly addictive drugs off the streets.
Only 1 in 20 U.S. adolescents is meeting national recommendations for sleeping, physical activity, and screen time, according to new research by The University of Texas Health Science Center at Houston (UTHealth).
During a study spanning nearly a decade, researchers at The Ohio State University College of Medicine, Houston Methodist Research Institute and Houston Methodist Cancer Center have linked the protein clusterin – for the first time -- to many different facets of cardiometabolic syndrome risk through its actions in the liver.
As an institution devoted to eliminating cancer for patients in Texas, the nation and around the world, The University of Texas MD Anderson Cancer Center is proud to uphold the mission of World Cancer Day, Feb.4, to unite the global population toward the goal of eradicating the disease.
Women with risk factors for heart disease like diabetes and a family history need to begin a prevention plan in their 30s and 40s so they can get ahead of the disease when they hit menopause
HARC released a special report today for public and private sector leaders that addresses how to fund critical infrastructure required to maintain the safety and well-being of cities and communities. The Green Paper is entitled “Funding Resilience in the Greater Houston Region: Synopsis from a Public-Private Sector Workshop.”
The first U.S. patient to participate in a global study of a stem cell therapy injected directly into the brain to treat stroke disability was enrolled in the clinical trial this week at The University of Texas Health Science Center at Houston (UTHealth).
Glioblastoma (GBM) does not attract robust T cell immune responses. FGL2 is highly expressed in GBM and when present in tumor cells, controls a specialized group of dendritic cells which activates T cells.
Nearly 1 in 5 fifth-graders has received violent injuries, the majority delivered by guns or knives, according to recently published research by The University of Texas Health Science Center at Houston (UTHealth).
By February, nearly 80 percent of Americans will give up on their New Year’s resolutions, but a Houston Methodist lifestyle coach says making a few simple changes can help people reach their goals.
A same-day procedural therapy to improve glucose control for Type 2 diabetes patients will be investigated in a pilot study at The University of Texas Health Science Center at Houston (UTHealth). Absalon D. Gutierrez, MD, and Nirav C. Thosani, MD, are among the first physician-researchers in the country to assess the safety and effectiveness of The Revita™ System, designed to help improve blood sugar levels without the need for additional medications.
The University of Texas MD Anderson Cancer Center and Dragonfly Therapeutics, Inc., today announced a strategic collaboration to bring Dragonfly’s TriNKET™ (tri-specific natural killer cell engager therapy) immunotherapy drug candidates to patients in clinical trials beginning in 2019.
Two grants totaling nearly $3.7 million will support the efforts of The University of Texas Health Science Center at Houston (UTHealth) to combat obesity and help Texas children achieve healthy lifestyles through the mission of the Michael & Susan Dell Center for Healthy Living.
Complication rates following invasive diagnostic procedures for lung abnormalities were twice as high in community settings compared to those reporter in lung screening trials, according to an MD Anderson study.
MD Anderson researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment with immune checkpoint blockade drugs effective against a variety of other cancers.
Rather than classifying based solely on HPV status, MD Anderson researchers have discovered a new biomarker for head and neck cancers that may enable clinicians to better predict patient outcomes and lower treatment intensity to reduce side effects.
Getting the flu vaccine is not only your best shot at beating the virus – it could help in other ways you may never have realized.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right